Zalcitabine。
文章的细节
-
引用
复制到剪贴板 -
谢尔顿乔丹,奥唐纳,莫尔斯GD
Zalcitabine。
安Pharmacother。1993年4月,27 (4):480 - 9。
- PubMed ID
-
8097417 (在PubMed]
- 文摘
-
目的:复习化学,细胞内代谢,药物动力学,和临床试验zalcitabine(2 ' 3 '双脱氧胞苷,监护系统)。数据来源:procedings英文文章和会议。索引术语zalcitabine, 2 ' 3 '双脱氧胞苷,监护系统。研究选择:除了制造商的包插入,可用期和I / II期研究综述。数据提取:临床经验与监护系统局限于不受控制的研究和扩大提供程序。艾滋病毒疾病的疗效评估仅仅是代理标记:CD4 +淋巴细胞计数和p24抗原决定。临床端点,疾病进展和存活率等,必须提供给美国食品和药物管理局(FDA)持续的批准。数据合成:美国食品和药物管理局已批准使用的监护系统结合齐多夫定(ZDV)治疗的艾滋病毒感染患者CD4 +淋巴细胞计数<或= 300 / mm3经历了重要的临床或免疫恶化。虽然监护系统具有相同的作用机制和其他核苷类似物,它是在摩尔的基础上更有效。药物在胃液pH值是稳定的和具有良好的生物利用度(约70 - 90),但正在迅速清除从等离子体(半衰期约1 - 3 h)。细胞内浓度的ddC三磷酸,活动形式,可能是与等离子体浓度有关,还可能会持续在细胞超过父药物坚持等离子体。 When used as primary therapy in patients with CD4+ < or = 300 cells/mm3, ddC/ZDV increased CD4+ lymphocyte counts and reduced plasma p24 antigen concentrations. In comparison to ZDV monotherapy data taken from other studies, ddC/ZDV appeared to demonstrate a more pronounced and sustained increase in CD4+ cell counts; however, this observation cannot be confirmed until the results of ZDV-controlled comparisons are available. Overall, 17-31 percent of the patients receiving the currently recommended initial dosage of ddC experience peripheral neuropathy. CONCLUSIONS: In combination with ZDV, ddC appears to augment the CD4+ cell response of ZDV monotherapy in the treatment of HIV infection for ZDV-naive patients, although controlled studies and rigorous statistical analyses are lacking at present. The efficacy of ddC/ZDV in patients who received prior treatment with ZDV monotherapy is unclear at the present.
beplay体育安全吗DrugBank数据引用了这篇文章
- 药物